10 Best Up and Coming Stocks with Highest Upside Potential
In this article, we will discuss the 10 Best Up and Coming Stocks with Highest Upside Potential.
Nuvalent Inc. (NUVL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 17,248,450 | $2,130,183,575 | 22.22% | |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 5,924,433 | $731,667,476 | +12% | 13.7% |
| 3. | HBK Investments David Costen Haley | 3,483,100 | $430,162,850 | 4.2% | |
| 4. | Deep Track Capital David Kroin | 1,783,322 | $220,240,267 | +30% | 3.21% |
| 5. | Perceptive Advisors Joseph Edelman | 1,580,505 | $195,192,368 | 2.93% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 650,000 | $21,775,000.00 | 650,000 | 2022-11-03 | Filing | |
| $33.50 | 149,253 | $4,999,975.50 | 3,577,267 | 2022-11-03 | Filing | |
| $17.00 | 735,000 | $12,495,000.00 | 3,428,014 | 2021-08-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $123.81 | 2,111 | $261,362.91 | 63,493 | 2026-07-09 | Filing | |
| $123.72 | 30,000 | $3,711,600.00 | 324,879 | 2026-07-06 | Filing | |
| $123.59 | 23,000 | $2,842,570.00 | 58,117 | 2026-07-01 | Filing | |
| $123.58 | 11,430 | $1,412,519.40 | 85,533 | 2026-07-01 | Filing | |
| $123.51 | 5,500 | $679,305.00 | 58,117 | 2026-06-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,585,619 | $689,823,951 | 0.01% | |
| 2. | 2,946,506 | $363,893,492 | 0.26% | |
| 3. | 2,589,282 | $319,776,327 | 0.01% | |
| 4. | 2,459,118 | $303,701,073 | 0.01% | |
| 5. | 2,091,044 | $258,243,982 | 0.01% |
News See All
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects
Nuvalent Inc. (NASDAQ:NUVL) is one of the best 52-week high stocks to buy right now. On November 24, Truist Securities initiated coverage of Nuvalent Inc.
12 Best 52-Week High Stocks to Buy Right Now
In this article, we take a look at the 12 Best 52-Week High Stocks to Buy Right Now.
Piper Sandler Initiates Nuvalent (NUVL) Amid Key Cancer Drug Catalysts
Nuvalent, Inc. (NASDAQ:NUVL) ranks among the best mid-cap stocks with huge upside potential. On August 19, Piper Sandler began coverage of Nuvalent, Inc.
12 Best Mid-Cap Stocks with Huge Upside Potential
In this article, we will take a look at the 12 Best Mid-Cap Stocks with Huge Upside Potential.
Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC
Nuvalent Inc. (NASDAQ:NUVL) is one of the best mid cap pharma stocks to buy.
10 Best Mid Cap Pharma Stocks to Buy
On July 14, Emily Field, the head of European pharma research at Barclays, appeared on CNBC to discuss which drug makers would be most impacted by 30% US tariffs on EU imports.
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer
Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential.
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year.
20 Takeover Rumors Hedge Funds Are Buying
This article will examine 20 takeover rumors that have prompted hedge funds to buy stocks. Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
Hedge Fund Resource Center